The efficacy of HDAC inhibitors in neoplasm treatment
DOI:
https://doi.org/10.12775/JEHS.2020.10.08.028Keywords
HDAC, inhibitors, cancer, hematologyAbstract
Introduction and purpose: Histone Deacetylases (HDACs) are associated with epigenetic regulation of gene expression. They are responsible of adequate action of not only histone proteins, but also crucial cell cycle proteins, such as p53, NF‐κB or alpha tubulin. Recent studies have shown the connection between expression of HDAC and carcinogenesis and impact of HDAC inhibitors on cancer therapy. The aim of the study was to review the recent studies on HDAC inhibitors efficiency in the treatment of hematologic neoplasms and solid tumors. It is a study review from 2010 to 2020 using the PubMed database and ClinicalTrials.gov. Description of state of knowledge: Most studies related to HDAC inhibitors impact in hematological neoplasms, such as multiple myeloma, Hodgkin lymphoma, T-cell lymphomas and acute myeloid leukemia. Among studied agents panobinostat, vorinostat and showed efficacy. Moreover, some HDACi demonstrated effectiveness in solid tumors treatment, foremost vorinostat in breast cancer and entinostat in non-small cell lung lymphoma. Summary: Including HDAC inhibitors in tumor treatment could be beneficial for patients, especially those with advanced, relapsed or refractory hematologic neoplasm. However, further studies are necessary to confirm their efficacy and to reveal side effects.References
IARC. Global Cancer Observatory (GLOBOCAN) Cancer Tomorrow 2018 Estimates. Available at. http://gco.iarc.fr/tomorrow. (access: 2020.03.27).
Weber JS, Yang JC, Atkins MB et al. Toxicities of immunotherapy for the practitioner. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2015;33:2092–2099. https://doi.org/10.1200/JCO.2014.60.0379
Stone ML, Chiappinelli KB, Li H et al. Topper MJ et al. Epigenetic therapy activates type i interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. Proc. Natl. Acad. Sci. USA. 2017;114:E10981–E10990. https://doi.org/10.1186/s13148-018-0602-0
Peedicayil J. Epigenetic approaches for bipolar disorder drug discovery. Expert Opinion on Drug Discovery. 2014; 9(8):917-930. https://doi.org/10.1517/17460441.2014.922537
Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 2007;1(1):19-25. https://doi.org/10.1016/j.molonc.2007.01.001
Witt O, Deubzer HE, Milde T et al. HDAC family: What are the cancer relevant targets? Cancer Lett. 2009;277(1):8-21. https://doi.org/10.1016/j.canlet.2008.08.016
San Jose-Eneriz E, Gimenez-Camino N, Agirre X et al. HDAC inhibitors in Acute Myeloid Leukemia. Cancers (Basel). 2019;11(11):1794. https://doi.org/10.3390/cancers11111794
Li Y, Seto E. HDACs and HDAC Inhibitors in Cancer Development and Therapy. Cold Spring Harb Perspect Med. 2016;6(10). https://doi.org/10.1101/cshperspect.a026831
San-Miguel JF, Hungria VTM, Yoon SS et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15(11):1195-1206. https://doi.org/10.1016/S1470-2045(14)70440-1
Richardson PG, Hungria VTM, Yoon SS et al. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by prior treatment. Blood. 2016;127(6):713-721. https://doi.org/10.1182/blood-2016-05-717777
Dimopoulos M, Siegel DS, Lonial S et al. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): A multicentre, randomised, double-blind study. Lancet Oncol. 2013;14(11):1129-1140. https://doi.org/10.1016/S1470-2045(13)70398-X
Hu B, Younes A, Westin JR, Turturro F et al. Phase-I and randomized phase-II trial of panobinostat in combination with ICE (Ifosfamide, carboplatin, etoposide) in relapsed or refractory classical hodgkin lymphoma. Leuk Lymphoma. 2018;59(4):863-870. https://doi.org/10.1080/10428194.2017.1359741
Von Tresckow B, Morschhauser F, Szer J et al. Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation. Leuk Lymphoma. 2017;58(1):222-225. https://doi.org/10.1080/10428194.2016.1182164
Child F, Ortiz-Romero PL, Alvarez R et al. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB–IVA mycosis fungoides/Sézary syndrome. Br J Dermatol. 2016;175(1):80-88. https://doi.org/10.1111/bjd.14427
Duvic M, Dummer R, Becker JC et al. Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial. Eur J Cancer. 2013;49(2):386-394. https://doi.org/10.1038/bjc.2013.616
Kim YH, Bagot M, Pinter-Brown L et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192-1204. https://doi.org/10.1016/S1470-2045(18)30379-6
Prebet T, Sun Z, Ketterling RP et al. Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. Br J Haematol. 2016;172(3):384-91. https://doi.org/10.1111/bjh.13832
Issa JP, Garcia-Manero G, Huang X et al; Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer. 2015;121(4):556-61. https://doi.org/10.1002/cncr.29085
McClure JJ, Li X, Chou CJ. Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics. Adv Cancer Res. 2018;138:183-211. https://doi.org/10.1016/bs.acr.2018.02.006
Yardley DA, Ismail-Khan RR, Melichar B et al. Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor. Journal of Clinical Oncology 2013;17:2128-2135. https://doi.org/10.1200/JCO.2012.43.7251
Luu T, Kim KP, Blanchard S et al. Phase IB Trial of Ixabepilone and Vorinostat in Metastatic Breast Cancer. Breast Cancer Res Treat. 2018;167(2):469-478. https://doi.org/10.1007/s10549-017-4516-x
Munster PN, Thurn KT, Thomas S et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011;104(12):1828-35. https://doi.org/10.1038/bjc.2011.156
Witta SE, Jotte RM, Konduri K et al. Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J Clin Oncol. 2012;30(18):2248-55. https://doi.org/10.1200/JCO.2011.38.9411
Tambo Y, Hosomi Y, Sakai H et al. Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy. Invest New Drugs. 2017;35(2):217-226. https://doi.org/10.1007/s10637-017-0435-2
Krug LM, Kindler HL, Calvert H et al. Vorinostat in 5 Patients With Advanced Malignant Pleural Mesothelioma Who Have Progressed on Previous Chemotherapy (VANTAGE-014): A Phase 3, Double-Blind, Randomised, Placebo-Controlled Trial. Lancet Oncol. 2015;16(4):447-56. https://doi.org/10.1016/S1470-2045(15)70056-2
Downloads
Published
How to Cite
Issue
Section
License
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 660
Number of citations: 0
